Bristol Myers Squibb and BioNTech announced a strategic partnership June 2 to co-develop and co-commercialize BioNTech’s next-generation cancer immunotherapy – BNT327 – across numerous solid tumor ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new ...

BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and ...

Bristol-Myers Squibb Company (($BMY)) has held its Q3 earnings call. Read on for the main highlights of the call.

BioNTech and Bristol Myers Squibb have announced a partnership for the global co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, which aims to improve ...

Bristol-Myers Squibb delivered a powerful second-quarter performance that sent shares climbing 2.2% as the pharmaceutical powerhouse demolished Wall Street expectations across multiple metrics. The ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD™ ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a ...

Bristol-Myers Squibb & Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, ...

Bristol Myers Squibb on Thursday beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs. The company now expects 2025 revenue to come in ...

Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus Bain Capital leads $300 million financing ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the ...